Direct to consumer responsibility: Medical neoliberalism in pharmaceutical advertising and drug development

Abstract

Purpose – This chapter explores the pharmaceutical industry's strategic utilization of empowerment discourse in two realms: direct-to-consumer advertising (DTCA) and clinical drug development.

Methodology – It draws upon two research projects that examine the role of the pharmaceutical industry in the political economy of healthcare in the United States: Ronald's policy analysis and participant observation of DTCA policy hearings and Fisher's participant observation and interviewing of the clinical trials industry.

Findings – Empowerment rhetoric is mobilized by the pharmaceutical industry to create specific expectations about patient-consumer behavior, particularly the responsibilities associated with the consumption of drugs.

Research implications – The social and economic implications of DTCA and drug trials must be understood within their broader historical and contemporary contexts of health advocacy, consumerism, and medical neoliberalism.

Practical implications – The chapter offers alternative constructions of healthcare subjects and pharmaceutical practices that can mitigate the power of the pharmaceutical industry and bring about better pharmaceutical governance.

Originality/value of chapter – By analyzing findings from two empirical projects, this chapter is able to shed light on trends in the pharmaceutical industry's discourse about empowerment and consumption from the clinical testing to marketing of new drugs.

Citation

Fisher, J.A. and Ronald, L.M. (2008), "Direct to consumer responsibility: Medical neoliberalism in pharmaceutical advertising and drug development", Chambré, S.M. and Goldner, M. (Ed.) Patients, Consumers and Civil Society (Advances in Medical Sociology, Vol. 10), Emerald Group Publishing Limited, Leeds, pp. 29-51. https://doi.org/10.1016/S1057-6290(08)10003-1